Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002043372 | SCV002301390 | benign | Tuberous sclerosis 2 | 2024-09-18 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003471266 | SCV004206817 | uncertain significance | Isolated focal cortical dysplasia type II | 2023-10-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004947044 | SCV005523407 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-08-15 | criteria provided, single submitter | clinical testing | The p.L48V variant (also known as c.142C>G), located in coding exon 2 of the TSC2 gene, results from a C to G substitution at nucleotide position 142. The leucine at codon 48 is replaced by valine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |